Analysts Anticipate Ovid Therapeutics Inc (NASDAQ:OVID) Will Announce Earnings of -$0.38 Per Share

Wall Street analysts expect that Ovid Therapeutics Inc (NASDAQ:OVID) will announce earnings per share of ($0.38) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.40). Ovid Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year over year growth rate of 28.3%. The firm is expected to issue its next quarterly earnings results on Thursday, November 14th.

On average, analysts expect that Ovid Therapeutics will report full year earnings of ($1.53) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.37). For the next financial year, analysts forecast that the business will report earnings of ($2.02) per share, with EPS estimates ranging from ($3.64) to ($0.65). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Ovid Therapeutics.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08.

OVID has been the topic of a number of recent research reports. ValuEngine raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Ovid Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $27.00 price objective on shares of Ovid Therapeutics in a report on Thursday, May 16th. Finally, Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $12.80.

NASDAQ OVID traded down $0.13 during trading on Friday, reaching $1.91. 58,565 shares of the company traded hands, compared to its average volume of 107,033. The company has a quick ratio of 5.84, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $1.99. Ovid Therapeutics has a 1-year low of $1.53 and a 1-year high of $6.83.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Ovid Therapeutics by 67.8% during the second quarter. Vanguard Group Inc. now owns 1,097,614 shares of the company’s stock valued at $2,030,000 after purchasing an additional 443,490 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Ovid Therapeutics by 29.8% in the 2nd quarter. Renaissance Technologies LLC now owns 471,609 shares of the company’s stock worth $872,000 after acquiring an additional 108,392 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Ovid Therapeutics by 41.0% in the 2nd quarter. Wells Fargo & Company MN now owns 442,604 shares of the company’s stock worth $819,000 after acquiring an additional 128,618 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Ovid Therapeutics by 37.4% in the 2nd quarter. Acadian Asset Management LLC now owns 211,490 shares of the company’s stock worth $392,000 after acquiring an additional 57,592 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Ovid Therapeutics by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock worth $231,000 after acquiring an additional 6,391 shares in the last quarter. 30.77% of the stock is currently owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Featured Article: What is the Stochastic Momentum Index (SMI)?

Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.